Clinical Trial: NRG BN007

NRG BN007

Status: Closed

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

BN007 is  closed to accrual, effective March 29, 2023.